经皮肺动脉成形术治疗大动脉炎相关肺动脉高压
这项前瞻性队列研究纳入50例完成经皮肺动脉成形术(PTPA)的大动脉炎相关肺动脉高压(TA-PH)患者和21例拒绝手术的患者,平均随访37±14个月,PTPA组3年生存率93.7%,非PTPA组76.2%(P=0.0096),PTPA与全因死亡风险降低相关(HR 0.18,95%CI 0.05-0.73,P=0.017),安全性可接受。
要点
- PTPA与TA-PH患者全因死亡风险显著降低相关(HR 0.18)。
- PTPA组3年生存率93.7%,非PTPA组76.2%。
- 严重并发症需无创正压通气者仅占0.7%(1/150次操作)。
核心结论
- PTPA倾向于降低TA-PH患者全因死亡风险,安全性可接受,可能是有前景的治疗选择。
主要发现
- 平均随访37±14个月,PTPA组死亡3例(6.0%),非PTPA组死亡6例(28.6%)。
- 3年生存率PTPA组93.7%,非PTPA组76.2%(log-rank P=0.0096)。
- Cox回归显示PTPA与全因死亡风险降低相关(HR 0.18;95%CI 0.05-0.73;P=0.017)。
- 围术期无死亡,150次操作中仅1次(0.7%)出现需无创正压通气的严重并发症。
临床怎么用
- 对于TA-PH患者,PTPA可作为考虑的治疗选项,需评估操作相关并发症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous transluminal pulmonary angioplasty (PTPA) is a treatment modality for chronic thromboembolic pulmonary hypertension, but whether it can be applied to Takayasu arteritis-associated pulmonary hypertension (TA-PH), another chronic obstructive pulmonary vascular disease, remains unclear. OBJECTIVES: This study sought to investigate the efficacy and safety of PTPA for TA-PH. METHODS: Between January 1, 2016, and December 31, 2019, a total of 50 patients with TA-PH who completed the PTPA procedure (the PTPA group) and 21 patients who refused the PTPA procedure (the non-PTPA group) were prospectively enrolled in this cohort study. The primary outcome was all-cause mortality. The safety outcomes included PTPA procedure-related complications. RESULTS: Baseline characteristics and medical therapies were similar between the PTPA group and the non-PTPA group. During a mean follow-up time of 37 ± 14 months, deaths occurred in 3 patients (6.0%) in the PTPA group and 6 patients (28.6%) in the non-PTPA group, contributing to the 3-year survival rate of 93.7% in the PTPA group and 76.2% in the non-PTPA group (P = 0.0096 for log-rank test). The Cox regression model showed that PTPA was associated with a significantly reduced hazard of all-cause mortality in TA-PH patients (HR: 0.18; 95% CI: 0.05-0.73; P = 0.017). No periprocedural death occurred. Severe complications requiring noninvasive positive pressure ventilation occurred in only 1 of 150 total sessions (0.7%). CONCLUSIONS: PTPA tended to be associated with a reduced risk of all-cause mortality with acceptable safety profiles and seemed to be a promising therapeutic option for TA-PH patients.
引用
- Zhou YP, Wei YP, Yang YJ, et al. Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022. PMID: 35422244. doi:10.1016/j.jacc.2022.01.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。